{"id":2345,"date":"2020-06-15T00:00:00","date_gmt":"2020-06-15T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2345"},"modified":"2020-06-15T00:00:00","modified_gmt":"2020-06-15T00:00:00","slug":"centogene-reports-first-quarter-2020-financial-results-and-corporate-progress","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pl\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/","title":{"rendered":"CENTOGENE publikuje wyniki finansowe i post\u0119py firmy za pierwszy kwarta\u0142 2020 r."},"content":{"rendered":"<p>Cambridge, MA, USA &amp; Rostock\/Berlin, Germany, June 15, 2020 (Globe Newswire) \u2013 Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today provided an update on its corporate progress and reported its financial results for the three months ended March 31, 2020.<\/p>\n<ul>\n<li>\u20ac12.1 million in revenues, an increase of 13% compared to three months ended March 31, 2019<\/li>\n<li>Continued expansion of global proprietary rare disease platform with approximately 3.0 billion weighted data points from over 530,000 patients representing 120 different countries as of March 31, 2020<\/li>\n<li>Over 60 biomarker programs, with over 25 biomarker programs (covering more than 22 diseases) having completed the first validation with mass spectrometry as of March 31, 2020<\/li>\n<li>Expansion of our COVID-19 testing, and commencement of production and distribution of a sample collection kit, CentoSwab\u2122, to support global efforts to address pandemic<\/li>\n<\/ul>\n<p>Prof. Arndt Rolfs, CEO of CENTOGENE, said, \u201cDuring the first quarter of 2020, we continued our focus on our core business of providing precise medical diagnosis of and accelerating drug development for rare hereditary diseases, while taking important steps to operate our business effectively during COVID-19 and support broader efforts to address this pandemic.&nbsp; We are pleased to report a growth of revenues by 13% for the first quarter 2020, driven by the continuous improvement in businesses of both our Pharma and Diagnostics segments.\u201d<\/p>\n<p>Prof. Arndt Rolfs continued, \u201cAs we continue to operate in a COVID-19 environment, it is our pleasure to report that while our quick, initial actions enabled 75% of employees to work from home, we have recently been able to bring back nearly all of our staff into the office by implementing regular testing.&nbsp; Additionally, we have further leveraged our diagnostic expertise to develop and offer a SARS-CoV-2 testing solution for patients around the world \u2013 beginning with the sampling system \u2018CentoSwab\u2122\u2019 and ending with the CENTOGENE-developed app for patient registration and medical reporting.&nbsp; We expect this diagnostic solution will help global communities begin to return to a new normal and prevent a further outbreak.&nbsp; With COVID-19 pandemic continued spreading across the globe, we have started to see its negative impact to our incumbent business, but expect our commercial COVID-19 testing will help offsetting such negative impact.\u201d<\/p>\n<h2 class=\"h3\">Nimble Response to COVID-19 and Continued Rare Disease Diagnostic Operations<\/h2>\n<h5>Spearheading Sustainable COVID-19 Testing Capabilities<\/h5>\n<p>In March 2020, CENTOGENE announced the commencement of its COVID-19 testing.&nbsp; Starting with employees and essential workers in Rostock, Germany, the Company further expanded the test offering to the nursing homes as well as to the high school students throughout Germany.&nbsp; Since May 2020, the Company is offering its tests to the rest of the world.&nbsp; In addition, CENTOGENE secured necessary reagents and supplies, such as CentoSwab\u2122, to support the logistics and fast diagnosis of COVID-19 since April 2020.<\/p>\n<h5>Acquisition of Hamburg Laboratory to Expand Testing Capacities<\/h5>\n<p>In April 2020, CENTOGENE announced the opening of a new laboratory in Hamburg, Germany to increase its testing capacity for the COVID-19 virus. The Rostock laboratory will continue to focus on the Company\u2019s core business in rare hereditary diseases and its\u2019 research efforts in biomarker development.<\/p>\n<h5><strong>Kontakt dla medi\u00f3w<\/strong><\/h5>\n<p>CENTOGENE<br \/> Sun Kim<br \/> Dyrektor ds. strategii i relacji inwestorskich<br \/> <a href=\"mailto:investor.relations@centogene.com\" title=\"Napisz e-mail\">investor.relations(at)centogene(dot)com&nbsp;<\/a><\/p>\n<p> Bridie Lawlor<br \/> Doradztwo FTI<br \/> +1.917.929.5684<br \/> <a href=\"mailto:bridie.lawlor@fticonsulting.com\" title=\"Napisz e-mail\">bridie.lawlor(at)fticonsulting(dot)com<\/a><br \/> &nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>W pierwszym kwartale 2020 roku nadal skupiali\u015bmy si\u0119 na naszej podstawowej dzia\u0142alno\u015bci, czyli zapewnianiu precyzyjnej diagnostyki medycznej i przyspieszaniu rozwoju lek\u00f3w na rzadkie choroby dziedziczne, podejmuj\u0105c jednocze\u015bnie wa\u017cne kroki maj\u0105ce na celu efektywne prowadzenie naszej dzia\u0142alno\u015bci w czasie pandemii COVID-19 i wspieranie szerszych dzia\u0142a\u0144 na rzecz zaradzenia tej pandemii.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2345","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pl\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"During the first quarter of 2020, we continued our focus on our core business of providing precise medical diagnosis of and accelerating drug development for rare hereditary diseases, while taking important steps to operate our business effectively during COVID-19 and support broader efforts to address this pandemic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pl\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-15T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuty\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress\",\"datePublished\":\"2020-06-15T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\"},\"wordCount\":552,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\",\"name\":\"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2020-06-15T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pl\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pl\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/","og_locale":"pl_PL","og_type":"article","og_title":"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress | CENTOGENE","og_description":"During the first quarter of 2020, we continued our focus on our core business of providing precise medical diagnosis of and accelerating drug development for rare hereditary diseases, while taking important steps to operate our business effectively during COVID-19 and support broader efforts to address this pandemic.","og_url":"https:\/\/www.centogene.com\/pl\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/","og_site_name":"CENTOGENE","article_published_time":"2020-06-15T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"admincg","Szacowany czas czytania":"3 minuty"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress","datePublished":"2020-06-15T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/"},"wordCount":552,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pl-PL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/","url":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/","name":"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2020-06-15T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-reports-first-quarter-2020-financial-results-and-corporate-progress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Kierowanie medycyn\u0105 precyzyjn\u0105","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pl\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/comments?post=2345"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2345\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/media?parent=2345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/categories?post=2345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/tags?post=2345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}